|
OmniComm Systems Signs Licensing Deal with West Coast Clinical Research Organization
FT. LAUDERDALE, Fla., August 6, 2009 /PRNewswire-FirstCall/ -- OmniComm
Systems, Inc. (OTC Bulletin Board: OMCM ), a leader in
integrated electronic data capture (EDC) solutions for clinical trials, announced today that it has entered into a
licensing agreement with a west coast Clinical Research Organization (CRO) for the use of ther TrialMaster™
solution in a Technology Transfer model. The agreement is expected to generate more than $1.1 million from
licensing, maintenance, hosting, and consulting fees for OmniComm over the next three years. It also allows this
leading CRO to expand its offering to its customers to include the latest in cutting edge technologies for electronic
data capture.
"We are extremely pleased to have been selected by this new client, and we believe that our unique platform of
eClinical solutions is being recognized within the clinical research community as a valuable and important tool for
facilitating the development of life-saving drugs and devices," said Stephen Johnson, OmniComm's COO. "With the
recent acquisitions of new, complementary technologies from ERT and Logos Technologies, Ltd., we now offer a
complete range of EDC solutions across the entire clinical trial spectrum for conducting clinical research. We believe
this will continue to increase our position as one of the market leaders in the EDC sector and we look forward to
helping more organizations streamline and manage their data collection efforts as they navigate the lengthy and
arduous FDA approval process."
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com)
provides customer-driven Internet solutions to pharmaceutical, biotechnology, research
and medical device organizations that conduct life changing clinical trial research.
OmniComm's growing base of satisfied customers is a direct result of the company's
commitment to deliver products and services that ensure ease of use, faster study
build, ease of integration and better performance. OmniComm's client intuitive pricing
model allows companies that range from small, to mid-size to large scale institutions
to safely and efficiently capitalize on their clinical research investments. OmniComm
Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida and offices
in Bonn, Germany, Tula, Russia, California, Connecticut, Georgia, Illinois, New
Jersey, New York, North Carolina and Tennessee.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements involve a number of risks and uncertainties such as the Company's
ability to obtain new contracts and accurately estimate net revenues due to uncertain
regulatory guidance, variability in size, scope and duration of projects, and internal
issues at the sponsoring client, integration of acquisitions, competitive factors,
technological development, and market demand. As a result, actual results may differ
materially from any financial outlooks stated herein. Further information on potential
factors that could affect the Company's financial results can be found in the Company's
Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission.
The Company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or otherwise.
CONTACT: Stephen Johnson at: + 1 954-377-1726
Back
|
